Thrombocytopenia

The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma.

The addition of temozolomide to radiation therapy prolonged OS for patients with both co-deleted and non-co-deleted grade 2 gliomas, according to study results.

SAN DIEGO — Epcoritamab exhibited encouraging efficacy among heavily pretreated patients with advanced chronic lymphocytic leukemia, according to study results presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Hydroxyurea conferred benefit to children and adults with hemoglobin SC disease, according to study results presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Eltrombopag conferred a higher rate of durable platelet response in the absence of rescue treatments than standard first-line treatments for children with newly diagnosed immune thrombocytopenia, according to study results.

Patients with metastatic gastrointestinal cancer may not need a 5-FU bolus as part of their treatment, according to retrospective study results.

Treatment with the novel antibody CM313 boosted platelet levels and demonstrated long-term durability among adults with immune thrombocytopenia, results from a phase 2 study showed.

Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.

Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.

Among patients with congenital thrombotic thrombocytopenic purpura, prophylactic therapy with recombinant ADAMTS13 restored normal levels of the enzyme, according to results of a randomized phase 3 study.